Tessa Romero
Stock Analyst at JP Morgan
(4.39)
# 322
Out of 5,129 analysts
77
Total ratings
52.54%
Success rate
21.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Neutral | $17 → $16 | $17.13 | -6.60% | 8 | Jan 20, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $70 → $74 | $64.85 | +14.11% | 6 | Jan 20, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $60 → $62 | $42.65 | +45.39% | 4 | Jan 9, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $20 → $25 | $27.15 | -7.92% | 8 | Jan 6, 2026 | |
| OCS Oculis Holding AG | Initiates: Overweight | $38 | $28.89 | +31.53% | 1 | Dec 19, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $12.20 | +22.95% | 8 | Nov 20, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $46 → $47 | $47.64 | -1.34% | 6 | Nov 18, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Underweight | $261 → $263 | $3.24 | +8,017.28% | 1 | Nov 18, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $33 → $31 | $22.70 | +36.56% | 11 | Nov 17, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $33 → $34 | $31.00 | +9.68% | 11 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.99 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $7.04 | +42.05% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $27.81 | +36.64% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $14.11 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $13.72 | +111.37% | 3 | Aug 13, 2024 |
Dyne Therapeutics
Jan 20, 2026
Maintains: Neutral
Price Target: $17 → $16
Current: $17.13
Upside: -6.60%
Cytokinetics
Jan 20, 2026
Maintains: Overweight
Price Target: $70 → $74
Current: $64.85
Upside: +14.11%
Xenon Pharmaceuticals
Jan 9, 2026
Maintains: Overweight
Price Target: $60 → $62
Current: $42.65
Upside: +45.39%
Agios Pharmaceuticals
Jan 6, 2026
Maintains: Neutral
Price Target: $20 → $25
Current: $27.15
Upside: -7.92%
Oculis Holding AG
Dec 19, 2025
Initiates: Overweight
Price Target: $38
Current: $28.89
Upside: +31.53%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $12.20
Upside: +22.95%
Scholar Rock Holding
Nov 18, 2025
Maintains: Overweight
Price Target: $46 → $47
Current: $47.64
Upside: -1.34%
Rocket Pharmaceuticals
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $3.24
Upside: +8,017.28%
ACADIA Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $33 → $31
Current: $22.70
Upside: +36.56%
Edgewise Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $31.00
Upside: +9.68%
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.99
Upside: -
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $7.04
Upside: +42.05%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $27.81
Upside: +36.64%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $14.11
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $13.72
Upside: +111.37%